Publication:
The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatment

Simple item page
dc.contributor.authorMarcellin, Patrick
dc.contributor.authorBonino, Ferruccio
dc.contributor.authorLau, George
dc.contributor.authorFarci, Patrizia
dc.contributor.authorYurdaydin, C.
dc.contributor.authorPiratvisuth, Teerha
dc.contributor.authorJin, R.
dc.contributor.authorHadziyannis, Stephanos J.
dc.contributor.authorLu, Zhimeng
dc.contributor.authorPopescu, Madalina
dc.contributor.buuauthorGürel, Selim
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentİç Hastalıkları Ana Bilim Dalı
dc.contributor.departmentGastroenteroloji Bilim Dalı
dc.date.accessioned2022-11-01T06:35:41Z
dc.date.available2022-11-01T06:35:41Z
dc.date.issued2006
dc.descriptionBu çalışma, 26-30 Nisan 2006 tarihleri arasında Vienna[Avusturya]’da düzenlenen 41. Annual Meeting of the European-Association-for-the-Study-of-the-Liver’da bildiri olarak sunulmuştur.tr_TR
dc.description.sponsorshipEuropean Assoc Study Liveren_US
dc.identifier.citationMarcellin, P. vd. (2006). ''The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatment''. Journal of hepatology, 44(Suplement 2), S275-S275.en_US
dc.identifier.endpageS275tr_TR
dc.identifier.issn0168-8278
dc.identifier.issueSupplement 2en_US
dc.identifier.startpageS275tr_TR
dc.identifier.urihttps://doi.org/10.1016/S0168-8278(06)80744-0
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0168827806807440
dc.identifier.urihttp://hdl.handle.net/11452/29287
dc.identifier.volume44tr_TR
dc.identifier.wos000237328100744
dc.indexed.wosSCIEen_US
dc.indexed.wosCPCISen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.collaborationYurt dışıtr_TR
dc.relation.collaborationYurt içitr_TR
dc.relation.journalJournal of hepatologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararasıtr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGastroenterology & hepatologyen_US
dc.subject.wosGastroenterology & hepatologyen_US
dc.titleThe majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatmenten_US
dc.typeMeeting Abstract
dc.wos.quartileQ1en_US
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Ana Bilim Dalı/Gastroenteroloji Bilim Dalıtr_TR
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

İndeksli Yayınlar / Indexed Publications